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Biological properties of the leukemic cells that sur­
vive chemotherapy have attracted attention of scien­
tists for many years but still remain obscure. Although 
chemotherapy has markedly evolved and current risk 
adapted protocols succeed for majority of children 
diagnosed with acute lymphoblastic leukemia, approxi­
mately 25% of patients develop a relapse. A relapse is 
also an adverse prognostic factor and requires a high 
risk adapted treatment and consequently lead to longer 
hospitalization and increased drug toxicity [1].
Currently, multidrug resistance is often associated 
with an efflux of cytotoxic compounds by transmembrane 
proteins. Most of them belong to ATP­binding cassette 
superfamily transporters (ABC transporters) [2, 3]. Role 
of MDR1 gene and its product P­glycoprotein in acute 
leukemia has been studied extensively by many investi­
gators. Some of the relevant publications confirmed an 
association between complete remission rates, overall 
and relapse­free survival and MDR1 gene or Pgp expres­
sion and/or function in acute leukemia [4–10]. Other 
studies failed to confirm these results [11–14]. Another 
ABC­transporter: breast cancer resistance protein (BCRP) 
and the corresponding gene also may play a role in acute 
leukemia but larger stu dies are needed to confirm this [10, 
13, 15, 16]. Major vault protein or lung resistance protein 
(LRP) is often associated with multidrug resistance [11, 
17, 18]. This protein is a part of the vault complex, a eu­
karyotic barrel shaped organelle with a recently described 
structure but still unknown cell function. Current data on 
partial colocalization of vaults with cytoskeletal elements, 
secretory organelles and nucleus suggests its function as 
a transporter [19–23]. Several studies have already dem­
onstrated a negative role of LRP expression in prognosis 
of acute leukemia [11, 17, 18, 24–26,]. In contrast, other 
investigators did not point towards a prognostic signifi­
cance of LRP [12, 27–29].
Surviving during chemotherapy also depends on 
ability of cells to undergo apoptosis. Antiapoptotic gene/
protein Bcl­2 is known to be associated with response 
and remission rate in acute leukemia, although there 
were publications with controversial data [30, 31].
In our study we attempted to investigate properties 
of leukemic cells by sorting out patients with different 
response to chemotherapy. We used a minimal residual 
disease (MRD) data on day 36 obtained with 3­colour 
flow cytometry for ALL patients as a reference. In view 
of MRD results, we assessed expression levels of mul­
tidrug resistance associated genes MDR1, LRP and 
BCRP, antiapoptotic gene Bcl-2 and P­glycoprotein 
expression and function in initial samples from children 
diagnosed with ALL.
methods
Patients. 19 children diagnosed with primary B­line­
age ALL were enrolled into the study. The patients age 
ranged from 1,9 to 18 years with median age at 5,5 years. 
The study was approved by the Ethical committee of the 
Research Center, samples were obtained under consi­
deration of all legal requirements.
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Minimal residual disease detection. 3­colour 
flow cytometry was used for MRD detection. Aliquots 
of bone marrow samples were incubated with mono­
clonal antibodies (MAb, Becton Dickinson) for 20 min 
at room temperature in dark. After that, erythrocytes 
were lysed by FACS Lysing Solution and samples were 
washed twice in Cell Wash buffer and fixed in para­
formaldehyde. The patterns of antigens expression 
was analyzed with flow cytometer FACSCan (Becton 
Dickinson) using CellQuestPro software. The following 
combinations of MAb were used: CD20/CD10/CD19, 
CD58/CD10/CD19, CD10/CD34/CD19, CD10/CD11a/
CD19 and CD45RA/CD10/CD19 conjugated with FITC, 
PE, PE­Cy5. At least 3 x 105 leukocytes were analyzed 
for each MAb combination. MRD positivity was defined 
as 0,01% of leukemic cells in a total count of leuko­
cytes in a bone marrow sample [32].
Cell cycle analysis. Leukemic cells of all used 
samples were isolated from bone marrow by gradient 
density centrifugation. To study cell cycle distribution 
leukemic cells were fixed in 70% ethanol. Then cells 
were washed and treated with RNAse and PI solution 
[33]. DNA content was evaluated using flow cytometry 
and ModFit program (Verity Software House).
P-gp expression and function. P­gp expres­
sion was evaluated with FITC­labeled 17F9 Mab (BD). 
P­gp function was tested by accumulation of JC­1 
(Molecular Probes) with and without cyclosporine A 
[34]. P­gp expression and function were analyzed by 
flow cytometer.
Real-time PCR. Cells were isolated as described 
in cell cycle analysis paragraph. Total RNA from leu­
kemic cells was extracted using Gen Elute Mammalian 
Total RNA Miniprep Kit (Sigma­Aldrich, St Louis, MO, 
USA). According to manufacturer’s protocol after 
first step (cell lysing) samples were stored at –70°. 
When needed, samples were thawed and RNA was 
extracted. Quantity and quality of obtained total RNA 
were defined with spectrophotometer Gene Quant 
RNA/DNA Calculator (GE Healthcare). Reaction of 
reverse transcription was carried out immediately after 
RNA extraction using Advantage RT­for­PCR Kit (BD) 
according to the manufacturer’s protocol.
We evaluated expression levels of experimental 
genes using real­time PCR (iCycler, BioRad). For calcu­
lating relative expression levels standard curves method 
was used. Each standard curve was genera ted from 
four 10­fold dilutions of cDNA obtained from IM­9 cell 
line. cDNA synthesized from one extraction of RNA from 
IM­9 cell line was used for creating standard curves for 
analyzed genes and as a calibrator (a sample used as the 
basis for comparative expression results). Each reaction 
plate contained standard curves for a target gene and a 
control gene. Normal gene GUS was used as a control 
gene [35]. cDNA from IM­9 cell line was used for creat­
ing the standard curves because it expresses the control 
and all the target genes. For all experimental samples, 
target quantity was determined by interpolating from the 
standard curve and then dividing by the target quantity 
of the calibrator. The calibrator, then, becomes the 1X 
sample, and all other quantities are expressed as an 
n­fold difference relative to the calibrator [36]. To avoid 
using numbers smaller than 1 (when there is less target 
RNA in the test sample than in the calibrator), all arbitrary 
units of gene expression levels in our study represent the 
fold­difference multiplied by 1000.
Amplifications were carried out in a total volume 
of 25 μl containing cDNA, Platinum Quantitative PCR 
SuperMix­UDG (Invitrogene, Carlsbad, CA, USA, final 
concentration of MgCl2 was raised to 4 mM), 300 nM 
of forward and reverse primer, and 200 nM of TaqMan 
probe. The following primers were used (5’ to 3’): Bcl­
2 forward primer: TTG GCC CCC GTT GCT T, reverse 
primer: CGG TTG TCG TAC CCC GTT CTC, TaqMan 
probe: FAM AGC GTG CGC CAT CCT TCC CAG BHQ1; 
MDR1 forward primer: AGG AAG ACA TGA CCA GGT ATG 
C, reverse primer: CCA ACA TCG TGC ACA TCA AAC, 
TaqMan probe: FAM CCT GGC AGC TGG AAG ACA AAT 
ACA CAA BHQ1; LRP forward primer: CAG CTG GCC ATC 
GAG ATC A, reverse primer: TCC AGT CTC TGA GCC TCA 
TGC, TaqMan probe: FAM CAA CTC CCA GGA AGC GGC 
GGC BHQ1; BCRP forward primer: TGG CTG TCA TGG 
CTT CAG TA, reverse primer: GCC ACG TGA TTC TTC 
CAC AA, TaqMan probe: FAM AGC AGG GCA TCG AGC 
TCT CAC CCT G BHQ1.
Statistical analysis. Results of experiments were 
presented as the median (lower quartile — upper quartile; 
valid number of cases tested). We used nonparametric 
Mann — Whitney U test to compare a certain property bet­
ween two groups and Spearman Rank order for correla­
tion tests (results presented as R value; P. of significance; 
valid number of pairs tested). All calculations and graphs 
were computed using software STATISTICA 6.1.
ResULts ANd dIsCUssIoN
Results of minimal residual disease monitoring at 
the end of the induction therapy is thought to be a very 
informative tool for prediction of a relapse [32]. Thus, 
we confronted data on drug resistance and apoptosis 
genes expression levels of all initial samples enrolled into 
the study with the results of MRD detection on day 36 of 
the same samples. MRD positivity was defined as 0,01% 
of leukemic cells in a total count of leukocytes in a bone 
marrow sample. By this criterion, all studied samples 
were divided into two groups: MRD positive (MRD+, n = 
9) and MRD negative (MRD–, n = 10). In MRD+ group the 
count of leukemic cells ranged from 0.03% to 0.3% with 
median at 0.08%. In MDR– group the quantity of leuke­
mic cells ranged from 0.001% to 0.006% with median at 
0.003%. Graphical summary of relative expression levels 
of studied genes in two groups of patients represented 
on Figure 1.
Medians of relative expression levels of MDR1 gene 
(Figure, а) were roughly comparable and in MRD+ group 
came to 22.8 (0.02–26.6; n = 9) vs 24.8 (3.9–41.4; n = 
10) in MRD– group. These results suggest that expres­
sion of MDR1 gene in bulk population of leukemic blasts 
at diagnosis does not reflect their multidrug resistance 
potential. Several similar studies confirmed this hypothesis 
[12, 14, 37]. P­glycoprotein expression may be an adverse 
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prognostic factor in adult (but not childhood) ALL [10]. We 
were able to supplement data on MDR1 gene expression 
with P­gp expression and function profiles for most studied 
samples. However, neither function no expression of P­gp 
protein displayed any significant differences in compared 
MRD+ and MRD– group (data not shown). Probably due to 
the small group of samples we were also unable to show 
statistically significant correlation between expression of 
MDR1 gene and P­gp expression and function.
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Figure. Relative expression levels of MDR1 (a), BCL-2 (b), LRP (c) 
and BCRP (d) genes in groups of ALL patients with negative (MRD–) 
and positive (MRD+) minimal residual disease at the end of the 
induction therapy. Medians, 25 and 75 percentiles are shown
According to many researchers, expression of Bcl­2 
protein has generally been associated with an adverse 
prognosis in CLL and AML [38, 39]. Other studies either 
did not confirm this or, in contrast, showed an improved 
EFS in childhood ALL [40–42]. Some authors specu­
lated that such controversy may be a result of post­
translational modifications of Bcl­2 [30, 43]. According 
to our study, Bcl-2 gene (Figure, b) showed a tendency 
(P = 0.1) to higher expression levels in MRD+ group with 
median at 5992.9 (4521.0–10362.0; n = 9) compared 
with 3183.6 (1947.9–6581.0; n = 10) in MRD– group.
Cellular distribution and a putative transport function 
of vault complexes suggest their role in drug resistance 
[44]. Therefore, increased expression level of the ma­
jor vault protein (or lung resistance protein) encoded 
by LRP gene potentially may serve as a marker of a 
multidrug resistance phenotype. It was shown that 
reduced intracellular retention of daunorubicin in vitro 
is associated with higher in vitro drug resistance and 
higher LRP levels, rather than Pgp or MRP expression 
[11, 17, 18]. Although, other publications showed no as­
sociation of LRP gene expression levels with response to 
therapy neither in ALL, no in AML patients [12, 27, 28]. 
In our studies LRP gene (Figure, c) relative expression 
levels were similar in both groups and came to 1934.9 
(1500.7–3490.4; n = 9) and 1408.5 (665.5–2917.1; 
n = 10) in MRD+ and MRD– group, respectively. 
Since its discovery in 1998, the role of expression 
level of BCRP in AML and ALL have been actively 
studied with contradictory results [10, 16]. According 
to some researchers, expression levels of BCRP gene 
in initial and relapsed samples of ALL patients were 
not different, and there were no association between 
this gene overexpression and unfavorable prognosis 
[15]. According to our data, the median of BCRP 
gene (Figure, d) expression levels in MRD+ group was 
considerably lower than that in MRD– group, namely 
76000.0 (48196.2–169230.8; n = 9) and 227967.2 
(16683.7–422222.2; n = 10), respectively, but statisti­
cal analysis showed no significant difference for this 
parameter. 
According to recent publication, higher proliferating 
activity within initial samples of ALL correlated with an 
increased drug sensitivity [45]. Similarly, higher complete 
remission rate in AML was associated with high prolifera­
tive activity [46]. Nevertheless, these findings contradict 
with some earlier publications [47, 48]. Cell cycle distri­
bution tests performed for present investigation showed 
a tendency (P = 0.15) to lower percentage of cells in S + 
G2M phase in MRD+ group: 10.1 (3.9–12.1; n = 7) com­
pared with 13.5 (8.2–17.2; n = 6) in MRD– group.
In conclusion, we investigated expression of 
multidrug resistance and apoptosis related genes in 
leukemic cells at diagnosis and MRD level at the end of 
induction therapy and could not find obvious relations 
between these parameters. Larger study is required 
to prove these results, although similar investigations 
showed association between an apoptosis­resistant 
protein profile, Pgp activity and MRD level in AML 
[49, 50]. It is also possible, that treatment response 
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depends on the expression of multidrug resistance 
and apoptosis associated genes not in total popula­
tion but in the putative leukemic stem cells population 
instead [51]. Apparently, identification of intrinsic 
qualities of chemoresistant cells would lead to a better 
understanding of mechanisms of drug resistance and 
may potentially give more opportunities for targeted 
therapy development.
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ЭКСПРЕССИЯ ГЕНОВ MDR1, LRP, BCRP И BCL-2 
ПРИ УСТАНОВЛЕНИИ ДИАГНОЗА ОЛЛ У ДЕТЕЙ: СРАВНЕНИЕ 
С РЕЗУЛЬТАТАМИ МОНИТОРИНГА МИНИМАЛЬНОЙ 
РЕЗИДУАЛЬНОЙ БОЛЕЗНИ ПОСЛЕ ИНДУКЦИОННОЙ ТЕРАПИИ
Цель: изучить свойства лейкозных клеток детей больных ОЛЛ с положительным и отрицательным результатом мониторинга 
минимальной резидуальной болезни после индукционной терапии. Методы: согласно результатам мониторинга минимальной 
резидуальной болезни (MRD) с помощью трехцветной проточной цитометрии на 36-й день больные были разделены на 2 группы: 
MRD– и MRD+. Для изучения уровней экспрессии генов MDR1, LRP, BCRP и BCL-2 в образцах костного мозга пациентов с 
диагнозом первичного ОЛЛ использовался метод относительной количественной ПЦР в режиме реального времени. Результаты: 
медианы уровней экспрессии гена MDR1 в изученных группах пациентов отличались незначительно и составили 22,8 (0,02–26,6; 
n = 9) в MRD+ и 24,8 (3,9–41,4; n = 10) в MRD–-группе. Тенденция к повышенной экспрессии гена BCL-2 выявлена в группе 
MRD+, где медиана составила 5992,9 (521,0–10362,0; n = 9), по сравнению с 3183,6 (1947,9–6581,0; n = 10) в группе MRD–. 
Относительная экспрессия гена LRP в изучаемых группах оказалась сходной, медианы составили 1934,9 (1500,7–3490,4; n = 9) 
и 1408,5 (665,5–2917,1; n = 10) в MRD+- и MRD–-группах соответственно. Медиана уровня экспрессии гена BCRP в группе 
MRD+ была значительно ниже таковой в группе MRD– — 76000,0 (48196,2–169230,8; n = 9) и 227967,2 (16683,7–422222,2; 
n = 10) соответственно, однако статистических анализ не подтвердил значимость различий. Выводы: при изучении уровней 
экспрессии генов MDR1, LRP, BCRP и BCL-2 в лейкозных клетках при установлении первичного диагноза ОЛЛ у детей и при 
мониторинге MRD после индукционной терапии не выявлена связь между данными параметрами.
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